TY - JOUR T1 - New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. JF - Blood//Blood Y1 - 2013 A1 - Daikeler, Thomas A1 - Labopin, Myriam A1 - Ruggeri, Annalisa A1 - Crotta, Alessandro A1 - Abinun, Mario A1 - Hussein, Ayad Ahmed A1 - Carlson, Kristina A1 - Cornillon, Jerome A1 - Diez-Martin, Jose L A1 - Gandemer, Virginie A1 - Faraci, Maura A1 - Lindemans, Caroline A1 - O'Meara, Anne A1 - Mialou, Valerie A1 - Renard, Marleen A1 - Sedlacek, Petr A1 - Sirvent, Anne A1 - Socie, Gerard A1 - Sora, Federica A1 - Varotto, Stefania A1 - Sanz, Jaime A1 - Voswinkel, Jan A1 - Vora, Ajay A1 - Yesilipek, M Akif A1 - Herr, Andree-Laure A1 - Gluckman, Eliane A1 - Farge, Dominique A1 - Rocha, Vanderson KW - *Autoimmune Diseases/et [Etiology] KW - *Cord Blood Stem Cell Transplantation/ae [Adverse Effects] KW - *Outcome Assessment (Health Care)/sn [Statistics & Numerical Data] KW - *Risk Assessment/sn [Statistics & Numerical Data] KW - Adolescent KW - Adult KW - Aged KW - Antibodies, Monoclonal, Murine-Derived/tu [Therapeutic Use] KW - Autoimmune Diseases/dt [Drug Therapy] KW - Child KW - Child, Preschool KW - Cyclosporine/tu [Therapeutic Use] KW - Female KW - Follow-Up Studies KW - Humans KW - Immunologic Factors/tu [Therapeutic Use] KW - Immunosuppressive Agents/tu [Therapeutic Use] KW - Infant KW - Male KW - Middle Aged KW - Multivariate Analysis KW - Outcome Assessment (Health Care)/mt [Methods] KW - Retrospective Studies KW - Risk Assessment/mt [Methods] KW - Risk Factors KW - Steroids/tu [Therapeutic Use] KW - Survival Analysis KW - Young Adult AB - To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0% +/- 1% at 1 year and 6.6% +/- 1% at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P < .001). ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n = 9; autoimmune thrombocytopenia, n = 11; and immune neutropenia, n = 1) and other tissues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n 1; membranous glomerulonephritis, n = 2; rheumatoid arthritis, n = 1; ulcerative colitis, n = 1; and systemic lupus erythematosus, n = 1). Four patients developed 2 ADs (3 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rheumatoid arthritis). By multivariate analysis, the main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001). Hematologic ADs were most often treated with steroids, rituximab, and cyclosporine. With a median follow-up of 26 months (range, 2-91), 6 of 52 patients died as a consequence of ADs. We conclude that CBT may be followed by potentially life-threatening, mainly hematologic ADs. M1 - a8g, 7603509 PB - Daikeler,Thomas. Eurocord, Hopital Saint Louis Assistance Publique des Hopitaux de Paris (AP-HP), University Paris VII, Paris, France. tdaikeler@uhbs.ch CY - United States VL - 121 SN - 1528-0020 CP - 6 L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=23247725 ID - 4220 ER -